KLB and metabolic dysfunction-associated steatohepatitis: In addition, phase 1/2 clinical trials of other FGF21 agonists (NCT03060538; agonistic anti-FGFR1/KLB antibody (BFKB8488A), NCT03298464; anti-FGFR1c/KLB antibody (MK-3655/NGM313), NCT03976401; an engineered Fc-FGF21 (AKR-001) and NCT04048135; a glycopegylated FGF21 (BIO89-100)) are underway or completed in patients with NAFLD or NASH (Table 1).